Effects of Rosiglitazone on Renal Hemodynamics and Proteinuria of Type 2 Diabetic Patients With Renal Insufficiency Due to Overt Diabetic Nephropathy

NCT00324675 · clinicaltrials.gov ↗

NA

Phase

COMPLETED

Status

28

Enrollment

OTHER

Sponsor class

Conditions

Type 2 Diabetes
Overt Diabetic Nephropathy

Interventions

DRUG: Rosiglitazone
DRUG: Placebo

Sponsor

Technische Universität Dresden